secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0001104659-25-058199
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Iovance stockholders elect all director nominees, approve equity plan and audit ratification at annual meeting
--------------------------------------------------------------------------------

- Annual meeting held June 10, 2025; 254,281,338 shares (76.1% of outstanding) represented.
- All seven director nominees elected; vote tallies ranged from 97.8M (Countouriotis) to 166.9M (Rothbaum).
- Non-binding advisory vote on executive compensation approved: 158.8M for, 14.5M against, 0.8M abstain.
- Ratification of Ernst & Young as independent auditor approved: 248.4M for, 4.9M against.
- Amendments to 2018 Equity Plan (+12.5M shares) and 2020 ESPP (+1M shares) approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925058199/0001104659-25-058199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925058199/tm2517622d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-058199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer